Table 1.
Baseline clinical features of 148 patients with metastatic nasopharyngeal carcinoma.
| Characteristic | Number (%) | CRP/Alb < 0.189, number (%) | CRP/Alb ≥ 0.189, number (%) | p value |
|---|---|---|---|---|
| Gender (male/female) | 124/24 (83.8/16.2) | 63/15 (80.8/19.2) | 61/9 (87.1/12.9) | 0.373 |
| Age, years (median/range) | 45/24–72 | 45/26–70 | 43.5/24–72 | 0.765 |
| KPS (median/range) | 90/60–100 | 90/60–100 | 90/60–100 | 0.276 |
| Number of involved sites (one/multiple) | 69/79 (46.6/53.4) | 42/36 (53.8/46.2) | 27/43 (38.6/61.4) | 0.071 |
| Synchronous metastasis (yes/no) | 43/105 (29.1/70.9) | 20/58 (25.6/74.4) | 23/47 (32.9/67.1) | 0.368 |
| Liver metastasis (yes/no) | 56/92 (37.8/62.2) | 28/50 (35.9/64.1) | 28/42 (40/60) | 0.615 |
| Lung metastasis (yes/no) | 69/79 (46.6/53.4) | 38/40 (48.7/51.3) | 31/39 (44.3/55.7) | 0.623 |
| Bone metastasis (yes/no) | 61/87 (41.2/58.8) | 28/50 (35.9/64.1) | 33/37 (47.1/52.9) | 0.184 |
| Smoking (yes/no) | 68/80 (45.9/54.1) | 36/42 (42.1/53.8) | 32/38 (45.7/54.3) | 1.000 |
| GPS (0/1/2) | 88/46/14 (59.5/31.1/9.4) | 52/20/6 (66.7/25.6/7.7) | 36/26/8 (51.4/37.1/11.4) | 0.169 |
| Serum LDH, U/L (median/range) | 202.5/25–2975 | 179.5/122–2821 | 230/25–2975 | 0.069 |
| EBV-DNA, copies/mL (median/range) | 4.82 × 104/0–9.13 × 107 | 3.49 × 104/0–9.87 × 106 | 5.32 × 105/0–9.13 × 107 | 0.013∗ |
| Chemotherapy regimen (TP/PF/TPF) | 12/45/91 (8.1/30.4/61.5) | 7/26/45 (9/33.3/57.7) | 5/19/46 (7.2/27.1/65.7) | 0.605 |
| Treatment response (CR + PR/PD + SD) | 107/41 (72.3/27.7) | 59/19 (75.6/24.4) | 48/22 (68.6/31.4) | 0.363 |
| NLR (median/range) | 3.3/1–35.2 | 2.8/1–14 | 4/1–35.2 | 0.001∗ |
| PLR (median/range) | 181/56.4–820 | 161/88–735 | 231/56.4–820 | 0.001∗ |
| Hemoglobin, g/L (median/range) | 131/43–171 | 132/43–171 | 123/82–162 | 0.019∗ |
CRP/Alb: C-reactive protein/albumin ratio; KPS: Karnofsky Performance Score; GPS: Glasgow Prognostic Score; NLR: neutrophil to lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; ∗p < 0.05.